TDC
EDIT icon

Thompson Davis & Co’s Editas Medicine EDIT Stock Holding History

Thompson Davis & Co’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		$20K Sell
625
-1,375
-69% -$44.4K 0.04% 326
2018
Q2 		$72K Buy
2,000
+625
+45% +$22.1K 0.17% 138
2018
Q1 		$46K Buy
+1,375
New +$49K 0.12% 178

Other funds holding EDIT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Thompson Davis & Co's EDIT Position: Q3 2018 in Review

Thompson Davis & Co reduced its Editas Medicine (EDIT) stake by 69% in Q3 2018, selling an estimated $44.4K and leaving 625 shares worth $20K. The position accounts for 0.04% of the portfolio, ranked #326.

Thompson Davis & Co first reported a position in EDIT in Q1 2018 and has held it in 3 quarters since. The position peaked at $72K in Q2 2018. 199 funds tracked by Wall St. Rank hold EDIT as of Q3 2018.

  • Thompson Davis & Co held 625 shares of Editas Medicine worth $20K as of Q3 2018.
  • Thompson Davis & Co sold 1,375 Editas Medicine shares in Q3 2018, an estimated $44.4K.
  • Editas Medicine made up 0.04% of Thompson Davis & Co's portfolio in Q3 2018, its #326 holding.
  • Thompson Davis & Co first reported a position in Editas Medicine in Q1 2018 and has held it in 3 quarters since.
  • Thompson Davis & Co's Editas Medicine position peaked at $72K in Q2 2018.
  • 199 funds tracked by Wall St. Rank held Editas Medicine as of Q3 2018.

Based on Thompson Davis & Co's 13F filing for Q3 2018, filed 14 Nov 2018.